版本:
中国

BRIEF-Newron Pharmaceuticals re-submits US NDA for Xadago

Sept 22 Newron Pharmaceuticals Spa :

* Re-submits US New Drug Application for Xadago (safinamide)

* As a class 2 resubmission, FDA is expected to complete its review of re-submission within 6 months of acceptance Source text for Eikon: Further company coverage: (Gdynia Newsroom)

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐